Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297318 | 0.83 | MAOB (0.71) | MAOB | |
| SCHEMBL9424210 | 0.72 | MAOB (0.57) | MAOB | |
| SCHEMBL14527001 | 0.72 | MAOB (1.00) | MAOB | |
| SCHEMBL9638028 | 0.72 | MAOB (0.70) | MAOB | |
| SCHEMBL7297313 | 0.72 | MAOB (0.56) | MAOB | |
| SCHEMBL27740555 | 0.70 | MAOB (0.56) | MAOB | |
| SCHEMBL29032391 | 0.69 | KDM4E (0.64) | MAOB | |
| SCHEMBL2617467 | 0.68 | FAAH (0.55) | MAOB | |
| SCHEMBL27037987 | 0.68 | MAOB (0.66) | MAOB | |
| SCHEMBL9462380 | 0.67 | MAOB (0.59) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325378-A | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | 柯巴斯医药有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11179370-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers | JENRIN DISCOVERY, LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210023054-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS | JENRIN DISCOVERY, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10617673-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, LLC (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2877173-B1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | JENRIN DISCOVERY INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180353478-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, LLC | 2018-12-13 | — | — | US | disclosed |
| EP-2023920-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | Jenrin Discovery (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2008144604-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1993560-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2007131219-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | JENRIN DISCOVERY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007106721-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | MAOB 2702/4885 |
| US-10617673-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | CNR1, CNR2, GPR119 | MAOB 3683/4885 |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | MAOB 3359/4885 |
| US-20210023054-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS | CNR1, CNR2, GPR119 | MAOB 3627/4885 |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | MAOB 2957/4885 |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | MAOB 3421/4885 |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | MAOB 3359/4885 |
| US-11179370-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers | CNR1, CNR2, GPR119 | MAOB 3627/4885 |
| US-20180353478-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR1, CNR2, GPR119 | MAOB 3683/4885 |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | CNR2, CNR1, GPR119 | MAOB 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.